



**Figure S7.** MPNST xenografts and effects with BCI and MEKi. **A**, Representative images of trichrome staining of PDX xenograft MPNST dosed with BCI 10 mg/kg, i.p. or vehicle once daily, 5x/wk for 21 days followed by treatment stoppage for 7 days. Scale bar is 100  $\mu$ m. **B**, Final tumor volumes of PDX xenograft MPNST dosed with BCI 10 mg/kg, i.p. or PD0325901 1.5mg/kg by oral gavage, or vehicle once daily, 5x/wk for 21 days (\*) represents  $P < 0.05$ . **C**, Tumor volume ( $\text{mm}^3$ ) in the S462.TY cell-based xenograft MPNST model dosed with PD0325901 1.5mg/kg by oral gavage ( $n=5$ ) and in combination with BCI 10 mg/kg, i.p. ( $n=7$ ) once daily, 5x/wk for 27 days versus control ( $n = 6$ ). By day 27, mice required sacrifice. Data points represents mean  $\pm$  SE. (\*) represents  $P < 0.05$  compared to vehicle. **D**, Representative images of hematoxylin and eosin (H&E)

staining in the TY and PDX xenograft MPNST mouse models which show necrosis (N) with BCI dosing compared to vehicle-treated tumors. Scale bar is 50 um.